Key Takeaways Alvotech shares have fallen 38% in 2025, underperforming the industry, sector and the S&P 500.Product revenue jumped 200% in H1 2025 to $205M, driven by Simlandi and Selarsdi sales.ALVO gained EU approval for Mynzepli and expanded partnerships with Dr. Reddy's and Advanz Pharma.Shares of biosimilar drugmaker Alvotech (ALVO) closed at$8.16 on Monday, near its 52-week low of $7.35.This underperformance is attributable to investor concerns over stiff competition in the biosimilar space, coupled ...